Personal information

Canada

Activities

Employment (2)

Geneseeq Technology Inc.: Toronto, Ontario, CA

2022-01-01 to present | Associate Director (Oncology R&D)
Employment
Source: Self-asserted source
Qiuxiang Ou

University of Alberta: Edmonton, AB, CA

2013-05-15 to 2016-08-01 | Postdoctoral fellow (Biological Sciences)
Employment
Source: Self-asserted source
Qiuxiang Ou

Education and qualifications (5)

University of Toronto: Toronto, Ontario, CA

2019-05 to 2020-04 | Project Management Certificate (School of Continuing Studies)
Education
Source: Self-asserted source
Qiuxiang Ou

Harvard University Extension School: Cambridge, MA, US

2019-02-01 to 2019-05-01 | Certification (Clinical Trial Design and Ethics)
Qualification
Source: Self-asserted source
Qiuxiang Ou

Philipp University of Marburg: Marburg, DE

2014 to 2014 | Visiting research fellow (Institute of Cytobiology)
Qualification
Source: Self-asserted source
Qiuxiang Ou

University of Alberta: Edmonton, AB, CA

2007 to 2013 | PhD student (Biological Sciences)
Qualification
Source: Self-asserted source
Qiuxiang Ou

Shanghai Jiao Tong University: Shanghai, Shanghai, CN

2003 to 2007 | Undergraduate (School of Life Sciences and Biotechnology)
Qualification
Source: Self-asserted source
Qiuxiang Ou

Works (50 of 56)

Items per page:
Page 1 of 2

The clinical utility of plasma circulating tumor DNA in the diagnosis and disease surveillance in non-diffuse large B-cell non-Hodgkin lymphomas

Future Oncology
2024-12-04 | Journal article
Contributors: Xiaoping Zhang; Li Yang; Minyi Zhu; Xiaotian Zhao; Yao Xiao; Jiaohui Pang; Liuqing Zhu; Qiuxiang Ou; Hai-Wen Ni; Jingyan Xu
Source: check_circle
Crossref

Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial

Clinical Cancer Research
2024-11-15 | Journal article
Contributors: Xin Wang; Xiaozheng Kang; Ruixiang Zhang; Liyan Xue; Jiaqi Xu; Xiaotian Zhao; Qiuxiang Ou; Nuo Yu; Guojie Feng; Jiao Li et al.
Source: check_circle
Crossref

Data from Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial

2024-11-15 | Preprint
Contributors: Xin Wang; Xiaozheng Kang; Ruixiang Zhang; Liyan Xue; Jiaqi Xu; Xiaotian Zhao; Qiuxiang Ou; Nuo Yu; Guojie Feng; Jiao Li et al.
Source: check_circle
Crossref

Supplementary Figure S1 from Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial

2024-11-15 | Preprint
Contributors: Xin Wang; Xiaozheng Kang; Ruixiang Zhang; Liyan Xue; Jiaqi Xu; Xiaotian Zhao; Qiuxiang Ou; Nuo Yu; Guojie Feng; Jiao Li et al.
Source: check_circle
Crossref

Supplementary Figure S2 from Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial

2024-11-15 | Preprint
Contributors: Xin Wang; Xiaozheng Kang; Ruixiang Zhang; Liyan Xue; Jiaqi Xu; Xiaotian Zhao; Qiuxiang Ou; Nuo Yu; Guojie Feng; Jiao Li et al.
Source: check_circle
Crossref

Supplementary Figure S3 from Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial

2024-11-15 | Preprint
Contributors: Xin Wang; Xiaozheng Kang; Ruixiang Zhang; Liyan Xue; Jiaqi Xu; Xiaotian Zhao; Qiuxiang Ou; Nuo Yu; Guojie Feng; Jiao Li et al.
Source: check_circle
Crossref

Supplementary Figure S4 from Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial

2024-11-15 | Preprint
Contributors: Xin Wang; Xiaozheng Kang; Ruixiang Zhang; Liyan Xue; Jiaqi Xu; Xiaotian Zhao; Qiuxiang Ou; Nuo Yu; Guojie Feng; Jiao Li et al.
Source: check_circle
Crossref

Supplementary Figure S5 from Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial

2024-11-15 | Preprint
Contributors: Xin Wang; Xiaozheng Kang; Ruixiang Zhang; Liyan Xue; Jiaqi Xu; Xiaotian Zhao; Qiuxiang Ou; Nuo Yu; Guojie Feng; Jiao Li et al.
Source: check_circle
Crossref

Supplementary Figure S6 from Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial

2024-11-15 | Preprint
Contributors: Xin Wang; Xiaozheng Kang; Ruixiang Zhang; Liyan Xue; Jiaqi Xu; Xiaotian Zhao; Qiuxiang Ou; Nuo Yu; Guojie Feng; Jiao Li et al.
Source: check_circle
Crossref

Supplementary Table S1 from Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial

2024-11-15 | Preprint
Contributors: Xin Wang; Xiaozheng Kang; Ruixiang Zhang; Liyan Xue; Jiaqi Xu; Xiaotian Zhao; Qiuxiang Ou; Nuo Yu; Guojie Feng; Jiao Li et al.
Source: check_circle
Crossref

Supplementary Table S2 from Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial

2024-11-15 | Preprint
Contributors: Xin Wang; Xiaozheng Kang; Ruixiang Zhang; Liyan Xue; Jiaqi Xu; Xiaotian Zhao; Qiuxiang Ou; Nuo Yu; Guojie Feng; Jiao Li et al.
Source: check_circle
Crossref

Supplementary Table S3 from Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial

2024-11-15 | Preprint
Contributors: Xin Wang; Xiaozheng Kang; Ruixiang Zhang; Liyan Xue; Jiaqi Xu; Xiaotian Zhao; Qiuxiang Ou; Nuo Yu; Guojie Feng; Jiao Li et al.
Source: check_circle
Crossref

Supplementary Table S4 from Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial

2024-11-15 | Preprint
Contributors: Xin Wang; Xiaozheng Kang; Ruixiang Zhang; Liyan Xue; Jiaqi Xu; Xiaotian Zhao; Qiuxiang Ou; Nuo Yu; Guojie Feng; Jiao Li et al.
Source: check_circle
Crossref

Supplementary Table S5 from Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial

2024-11-15 | Preprint
Contributors: Xin Wang; Xiaozheng Kang; Ruixiang Zhang; Liyan Xue; Jiaqi Xu; Xiaotian Zhao; Qiuxiang Ou; Nuo Yu; Guojie Feng; Jiao Li et al.
Source: check_circle
Crossref

Supplementary Table S6 from Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial

2024-11-15 | Preprint
Contributors: Xin Wang; Xiaozheng Kang; Ruixiang Zhang; Liyan Xue; Jiaqi Xu; Xiaotian Zhao; Qiuxiang Ou; Nuo Yu; Guojie Feng; Jiao Li et al.
Source: check_circle
Crossref

Supplementary Table S7 from Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial

2024-11-15 | Preprint
Contributors: Xin Wang; Xiaozheng Kang; Ruixiang Zhang; Liyan Xue; Jiaqi Xu; Xiaotian Zhao; Qiuxiang Ou; Nuo Yu; Guojie Feng; Jiao Li et al.
Source: check_circle
Crossref

Supplementary Table S8 from Chemoradiotherapy and Subsequent Immunochemotherapy as Conversion Therapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase II NEXUS-1 Trial

2024-11-15 | Preprint
Contributors: Xin Wang; Xiaozheng Kang; Ruixiang Zhang; Liyan Xue; Jiaqi Xu; Xiaotian Zhao; Qiuxiang Ou; Nuo Yu; Guojie Feng; Jiao Li et al.
Source: check_circle
Crossref

Comprehensive genomic profiling of pulmonary spindle cell carcinoma using tissue and plasma samples: insights from a real‐world cohort analysis

The Journal of Pathology: Clinical Research
2024-05 | Journal article
Contributors: Yi Sun; Shilei Qin; Song Wang; Jiaohui Pang; Qiuxiang Ou; Weiquan Liang; Hai Zhong
Source: check_circle
Crossref

Identification of TCR rearrangements specific for genetic alterations in EGFR-mutated non-small cell lung cancer: results from the ADJUVANT-CTONG1104 trial

Cancer Immunology, Immunotherapy
2023-05 | Journal article
Contributors: Cunte Chen; Siyang Maggie Liu; Yedan Chen; Qiuxiang Ou; Hua Bao; Ling Xu; Yikai Zhang; Jia-Tao Zhang; Wenzhao Zhong; Qing Zhou et al.
Source: check_circle
Crossref

Pan‐cancer molecular analysis of EGFR large fragment deletion in the Asian population

Cancer Medicine
2023-04 | Journal article
Contributors: Jun Pu; Huannan Guo; Ruoying Yu; Qiuxiang Ou; Hua Bao; Xue Wu; Sanyuan Tang; Qingyong Chang
Source: check_circle
Crossref

Tumor-Naïve Circulating Tumor DNA as an Early Response Biomarker for Patients Treated With Immunotherapy in Early Phase Clinical Trials

JCO Precision Oncology
2023-04 | Journal article
Contributors: Enrique Sanz-Garcia; Sofia Genta; Xiaoxi Chen; Qiuxiang Ou; Daniel V. Araujo; Albiruni R. Abdul Razak; Aaron R. Hansen; Anna Spreafico; Hua Bao; Xue Wu et al.
Source: check_circle
Crossref

Clinical and molecular characteristics of kinase domain duplications across diverse cancer types in the Chinese population

Cancer Medicine
2023-03 | Journal article
Contributors: Xiaojing Lai; Ruoying Yu; Qiuxiang Ou; Hua Bao; Xue Wu; Yang Shao; Yang Li; Ying Zhang; Qingqing Ding
Source: check_circle
Crossref

NTRK fusion positive colorectal cancer is a unique subset of CRC with high TMB and microsatellite instability

Cancer Medicine
2022-07 | Journal article
Contributors: Hui Wang; Zhi‐Wei Li; Qiuxiang Ou; Xue Wu; Misako Nagasaka; Yang Shao; Sai‐Hong Ignatius Ou; Yu Yang
Source: check_circle
Crossref

Poor prognosis of intra‐tumoural TRBV6‐6 variants in EGFR‐mutant NSCLC: Results from the ADJUVANT‐CTONG1104 trial

Clinical and Translational Medicine
2022-04 | Journal article
Contributors: Cunte Chen; Siyang Maggie Liu; Yedan Chen; Ming Han; Qiuxiang Ou; Hua Bao; Ling Xu; Yikai Zhang; Jia‐Tao Zhang; Wenzhao Zhong et al.
Source: check_circle
Crossref

Correlation of PD-L1 Expression with Clinicopathological and Genomic Features in Chinese Non-Small-Cell Lung Cancer

Journal of Oncology
2022-04-11 | Journal article
Contributors: Yue Li; Chong Li; Ya Jiang; Xue Han; Sisi Liu; Xiuxiu Xu; Wanxiangfu Tang; Qiuxiang Ou; Hua Bao; Xue Wu et al.
Source: check_circle
Crossref

Predictive value of TCR Vβ-Jβ profile for adjuvant gefitinib in EGFR mutant NSCLC from ADJUVANT-CTONG 1104 trial

JCI Insight
2022-01-11 | Journal article
Contributors: Cunte Chen; Si-Yang Maggie Liu; Yedan Chen; Qiuxiang Ou; Hua Bao; Ling Xu; Yikai Zhang; Wenzhao Zhong; Qing Zhou; Xue-Ning Yang et al.
Source: check_circle
Crossref

Favorable Response to Olaparib in a Patient with Cancer of Unknown Primary Carrying a Germline BRCA1 R71K Mutation

OncoTargets and Therapy
2021-11 | Journal article
Contributors: Xiaomeng Jia; Shanshan Zhao; Xiang Li; Li Lv; Xin Chen; Evenki Pan; Qiuxiang Ou; Chen Song; Siwen Sun; Jinbo Zhao et al.
Source: check_circle
Crossref

Genomic characterization and outcome evaluation of kinome fusions in lung cancer revealed novel druggable fusions.

NPJ precision oncology
2021-09-10 | Journal article
Part of PMID: 34508169
Source: Self-asserted source
Qiuxiang Ou

Clinical metagenomic sequencing for rapid diagnosis of pneumonia and meningitis caused by Chlamydia psittaci.

World journal of clinical cases
2021-09-01 | Journal article
Part of PMID: 34621820
Source: Self-asserted source
Qiuxiang Ou

Targeting FGFR in non-small cell lung cancer: implications from the landscape of clinically actionable aberrations of FGFR kinases.

Cancer biology & medicine
2021-03-12 | Journal article
Source: Self-asserted source
Qiuxiang Ou

Clearance of circulating tumor DNA in a high-risk stage-IV rectal carcinoma patient with synchronous liver metastases after conversion surgery is correlated with pathologic complete response

Therapeutic Advances in Gastrointestinal Endoscopy
2021-01 | Journal article
Contributors: Yingying Huang; Wenzhuo Jia; Lijun Wang; Qiuxiang Ou; Xue Wu; Baocai Xing
Source: check_circle
Crossref

Lung adenocarcinoma patients with novel ALK fusion variants and their clinical responses to ALK inhibitors.

Cancer communications (London, England)
2021-01-12 | Journal article
Part of PMC: PMC7896746
Source: Self-asserted source
Qiuxiang Ou

Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib‐based combination therapy: A real‐world experience of off‐label ibrutinib use

Cancer Medicine
2020-11 | Journal article
Contributors: Feili Chen; Diwen Pang; Hanguo Guo; Qiuxiang Ou; Xue Wu; Xinmiao Jiang; Xiaojuan Wei; Sichu Liu; Ling Huang; Zhanli Liang et al.
Source: check_circle
Crossref

Molecular and clinicopathological characteristics of ROS1‐rearranged non‐small‐cell lung cancers identified by next‐generation sequencing

Molecular Oncology
2020-11 | Journal article
Contributors: Meiying Cui; Yuchen Han; Pan Li; Jianying Zhang; Qiuxiang Ou; Xiaoling Tong; Ruiying Zhao; Nan Dong; Xue Wu; Wencai Li et al.
Source: check_circle
Crossref

Clinical and molecular characteristics of Chinese non‐small cell lung cancer patients with ERBB2 transmembrane domain mutations

Molecular Oncology
2020-08 | Journal article
Contributors: Yun Fan; Jinrong Qiu; Ruoying Yu; Ran Cao; Xiaoxi Chen; Qiuxiang Ou; Xue Wu; Yang W. Shao; Misako Nagasaka; Jiexia Zhang et al.
Source: check_circle
Crossref

Distinct genomic traits of acral and mucosal melanomas revealed by targeted mutational profiling

Pigment Cell & Melanoma Research
2020-07 | Journal article
Contributors: Zhengyun Zou; Qiuxiang Ou; Yu Ren; Qing Lv; Lanqun Qin; Lianjun Zhao; Shu Su; Xue Wu; Hua Bao; Ao Wang et al.
Source: check_circle
Crossref

Comprehensive genomic profiling aids in understanding the lesion origins of a patient with six synchronous invasive lung adenocarcinomas: a case study

BMC Pulmonary Medicine
2020-04-03 | Journal article
Part of ISSN: 1471-2466
Source: Self-asserted source
Qiuxiang Ou

Pretreatment hemoglobin level as a predictor to evaluate the efficacy of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer

Therapeutic Advances in Medical Oncology
2020-01 | Journal article
Contributors: Zhibo Zhang; Fan Zhang; Fang Yuan; Ye Li; Junxun Ma; Qiuxiang Ou; Zhefeng Liu; Bo Yang; Lijie Wang; Haitao Tao et al.
Source: check_circle
Crossref

Distribution of NRG1 Gene Fusions in a Large Population of Chinese Patients with NSCLC.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
2019-12-01 | Journal article
Source: Self-asserted source
Qiuxiang Ou

Glycogen branching enzyme controls cellular iron homeostasis via Iron Regulatory Protein 1 and mitoNEET.

Nature communications
2019-11-29 | Journal article
Source: Self-asserted source
Qiuxiang Ou

Genes associated with increased brain metastasis risk in non–small cell lung cancer: Comprehensive genomic profiling of 61 resected brain metastases versus primary non–small cell lung cancer (Guangdong Association Study of Thoracic Oncology 1036)

Cancer
2019-10-15 | Journal article
Contributors: Hongsheng Wang; Qiuxiang Ou; Delan Li; Tao Qin; Hua Bao; Xue Hou; Kaicheng Wang; Fang Wang; Qianqian Deng; Jianzhong Liang et al.
Source: check_circle
Crossref

Evidence of NTRK1 Fusion as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC: Results From a Large-Scale Survey of NTRK1 Fusions in Chinese Patients With Lung Cancer.

Clinical lung cancer
2019-09-26 | Journal article
Source: Self-asserted source
Qiuxiang Ou

Clinical outcomes of EGFR kinase domain duplication to targeted therapies in NSCLC

International Journal of Cancer
2019-06 | Journal article
Contributors: Jinguang Wang; Xingya Li; Xingyang Xue; Qiuxiang Ou; Xue Wu; Ying Liang; Xiaonan Wang; Ming You; Yang W. Shao; Zhihong Zhang et al.
Source: check_circle
Crossref

Molecular genetic characterization reveals linear tumor evolution in a pulmonary sarcomatoid carcinomas patient with a novel PHF20-NTRK1 fusion: a case report

BMC Cancer
2019-06-17 | Journal article
Source: Self-asserted source
Qiuxiang Ou

Mutation Profile of Resected EGFR‐Mutated Lung Adenocarcinoma by Next‐Generation Sequencing

The Oncologist
2019-03-14 | Journal article
Source: Self-asserted source
Qiuxiang Ou

Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib

Lung Cancer
2018 | Journal article
EID:

2-s2.0-85041504741

Contributors: Liu, Y.; Li, Y.; Ou, Q.; Wu, X.; Wang, X.; Shao, Y.W.; Ying, J.
Source: Self-asserted source
Qiuxiang Ou via Scopus - Elsevier

Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non–small cell lung cancer patients

Clinical Cancer Research
2018 | Journal article
EID:

2-s2.0-85048805852

Contributors: Yang, Z.; Yang, N.; Ou, Q.; Xiang, Y.; Jiang, T.; Wu, X.; Bao, H.; Tong, X.; Wang, X.; Shao, Y.W. et al.
Source: Self-asserted source
Qiuxiang Ou via Scopus - Elsevier

Mechanisms of primary resistance to EGFR targeted therapy in advanced lung adenocarcinomas

Lung Cancer
2018 | Journal article
EID:

2-s2.0-85051007658

Contributors: Jin, Y.; Shi, X.; Zhao, J.; He, Q.; Chen, M.; Yan, J.; Ou, Q.; Wu, X.; Shao, Y.W.; Yu, X.
Source: Self-asserted source
Qiuxiang Ou via Scopus - Elsevier

Durable Clinical Response to Crizotinib in IRF2BP2-NTRK1 Non–small-cell Lung Cancer

Clinical Lung Cancer
2018-12-31 | Journal article
Source: Self-asserted source
Qiuxiang Ou

Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer

Lung Cancer
2018-11-24 | Journal article
Source: Self-asserted source
Qiuxiang Ou
Items per page:
Page 1 of 2

Peer review (2 reviews for 2 publications/grants)

Review activity for BMC cancer (1)
Review activity for Journal of Advanced Research (1)